Research Progress of Multiparametric Magnetic Resonance Imaging in Predicting Extraprostatic Extension of Prostate Cancer

APM

Advances in Precision Medicine

2424-85922424-9106

WHIOCE PUBLISHING PTE. LTD.

10.18063/APM.v11i4.1869

Article

Research Progress of Multiparametric Magnetic Resonance Imaging in Predicting Extraprostatic Extension of Prostate Cancerhttps://artdesignp.com/journal/APM/11/4/10.18063/APM.v11i4.1869DengAiqing

2026

114

2026-04-26

Extraprostatic extension (EPE) of prostate cancer is a key pathological feature that affects patient prognosis and the choice of treatment strategy. Accurate prediction of EPE is of significant clinical value in developing individualized treatment plans. Multiparametric magnetic resonance imaging (mpMRI), with its non-invasiveness, high spatial resolution, and multi-sequence imaging capabilities, has become a core imaging method for preoperative assessment of EPE. However, current imaging diagnosis of EPE still faces challenges such as high subjectivity, lack of standardized diagnostic criteria, and relatively low sensitivity in detecting minor extensions. In recent years, continuous breakthroughs in radiomics and artificial intelligence technologies are expected to significantly enhance the diagnostic performance of mpMRI. This article systematically reviews the optimization strategies of mpMRI imaging technology in the assessment of EPE in prostate cancer, explores the development from empirical interpretation to precise quantitative analysis of mpMRI features, focuses on the current application of radiomics in mpMRI-based prediction of EPE, and deeply analyzes the limitations of mpMRI in evaluating minor EPE. By integrating existing research evidence, it aims to provide clinicians with precise diagnostic strategies for EPE based on mpMRI, thereby contributing to the advancement of individualized diagnosis and treatment of prostate cancer.Multiparametric magnetic resonance imaging,Prostate cancer,Extraprostatic extension

[1] Bray F, Laversanne M, Sung H, et al., 2024, Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin, 74(3): 229–263. [2] Wilt TJ, Vo TN, Langsetmo L, et al., 2020, Radical Prostatectomy or Observation for Clinically Localized Prostate Cancer: Extended Follow-up of the Prostate Cancer Intervention Versus Observation Trial (PIVOT). Eur Urol, 77(6): 713–724. [3] Hamdy FC, Donovan JL, Lane JA, et al., 2016, 10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer. N Engl J Med, 375(15): 1415–1424. [4] Robesti D, Russo P, Fallara G, et al., 2026, Nerve-Sparing in High-Risk Prostate Cancer: Advantages and Pitfalls of Current Strategies and Technologies. Cancers (Basel), 18(6): 945. [5] Chuang HW, Wu S, Lin SX, et al., 2023, Detection of Extraprostatic Extension by Transperineal Multiparametric Magnetic Resonance Imaging-Ultrasound Fusion Targeted Combined with Systemic Template Prostate Biopsy. Diagn Pathol, 18(1): 101. [6] Sanguedolce F, Tedde A, Granados L, et al., 2024, Defining the Role of Multiparametric MRI in Predicting Prostate Cancer Extracapsular Extension. World J Urol, 42(1): 37. [7] Lin Y, Johnson LA, Fennessy FM, et al., 2024, Prostate Cancer Local Staging with Magnetic Resonance Imaging. Radiol Clin North Am, 62(1): 93–108. [8] Mehammed AH, Worke AB, Buser AA, et al., 2024, Positive Predictive Value of High-Grade Prostate Imaging and Reporting Data System V2.1 Magnetic Resonance Imaging Findings for Prostate Cancer. Ethiop J Health Sci, 34(Spec Iss 1): 23–30. [9] Wang JG, Huang BT, Huang L, et al., 2023, Prediction of Extracapsular Extension in Prostate Cancer Using the Likert Scale Combined with Clinical and Pathological Parameters. Front Oncol, 13: 1229552. [10] Onay A, Ertas G, Vural M, et al., 2020, The Role of T2-Weighted Images in Assessing the Grade of Extraprostatic Extension of the Prostate Carcinoma. Abdom Radiol (NY), 45(10): 3293–3300. [11] Singla A, Deep N, Naik S, et al., 2023, Correlation of Multiparametric MRI with Histopathological Grade of Peripheral Zone Prostate Carcinoma. J Cancer Res Ther, 19(Suppl 2): S569–S576. [12] Donati OF, Mazaheri Y, Afaq A, et al., 2014, Prostate Cancer Aggressiveness: Assessment with Whole-Lesion Histogram Analysis of the Apparent Diffusion Coefficient. Radiology, 271(1): 143–152. [13] Lewin M, Laurent-Bellue A, Desterke C, et al., 2022, Evaluation of Perfusion CT and Dual-Energy CT for Predicting Microvascular Invasion of Hepatocellular Carcinoma. Abdom Radiol (NY), 47(6): 2115–2127. [14] Li M, Yang L, Yue Y, et al., 2020, Use of Radiomics to Improve Diagnostic Performance of PI-RADS v2.1 in Prostate Cancer. Front Oncol, 10: 631831. [15] Guerra A, Flor-de-Lima B, Freire G, et al., 2023, Radiologic-Pathologic Correlation of Prostatic Cancer Extracapsular Extension (ECE). Insights Imaging, 14(1): 88. [16] Merder E, Arıman A, Altunrende F, 2021, A Modified Partın Table to Better Predict Extracapsular Extension in Clinically Localized Prostate Cancer. Urol J, 18(1): 74–80. [17] Gumus KZ, Menendez M, Baerga CG, et al., 2025, Investigation of Radiomic Features on MRI Images to Identify Extraprostatic Extension in Prostate Cancer. Comput Methods Programs Biomed, 259: 108528. [18] Felker ER, Margolis DJ, Nassiri N, et al., 2016, Prostate Cancer Risk Stratification with Magnetic Resonance Imaging. Urol Oncol, 34(7): 311–319. [19] Hüttl AB, Korda D, Lénárd MZ, et al., 2020, Our Initial Experiences with mpMRI-Ultrasound Fusion-Guided Prostate Biopsy. Orv Hetil, 161(52): 2188–2194. [20] Reisæter LAR, Halvorsen OJ, Beisland C, et al., 2020, Assessing Extraprostatic Extension with Multiparametric MRI of the Prostate: Mehralivand Extraprostatic Extension Grade or Extraprostatic Extension Likert Scale? Radiol Imaging Cancer, 2(1): e190071. [21] Wu X, Yao W, 2026, Artificial Intelligence Models Integrating Preoperative Prostate MRI and Clinical Parameters for Predicting Extraprostatic Extension: A Systematic Review and Meta-Analysis. J Surg Oncol, 133(3): 406–415. [22] Xiang Y, Yao H, Lin P, et al., 2025, A Multiparametric MRI-Based Model for Decoding Extraprostatic Extension in Prostate Cancer via Habitat-Guided Radiomics and Clinical Integration. Acad Radiol, 32(10): 5975–5986. [23] Arslan A, Karaarslan E, Güner AL, et al., 2022, Comparing the Diagnostic Performance of Multiparametric Prostate MRI Versus 68Ga-PSMA PET-CT in the Evaluation Lymph Node Involvement and Extraprostatic Extension. Acad Radiol, 29(5): 698–704. [24] Park KJ, Kim MH, Kim JK, 2020, Extraprostatic Tumor Extension: Comparison of Preoperative Multiparametric MRI Criteria and Histopathologic Correlation after Radical Prostatectomy. Radiology, 296(1): 87–95. [25] van den Berg I, Soeterik TFW, van der Hoeven E, et al., 2023, The Development and External Validation of Artificial Intelligence-Driven MRI-Based Models to Improve Prediction of Lesion-Specific Extraprostatic Extension in Patients with Prostate Cancer. Cancers (Basel), 15(22): 2452. [26] Liu BC, Ding XH, Xu HH, et al., 2026, Preoperative Assessment of Extraprostatic Extension in Prostate Cancer Using an Interpretable Tabular Prior-Data Fitted Network-Based Radiomics Model From MRI. J Magn Reson Imaging, 63(1): 98–112. [27] Gatti M, Faletti R, Gentile F, et al., 2022, mEPE-Score: A Comprehensive Grading System for Predicting Pathologic Extraprostatic Extension of Prostate Cancer at Multiparametric Magnetic Resonance Imaging. Eur Radiol, 32(7): 4942–4953. [28] Ling SW, de Jong AC, Schoots IG, et al., 2021, Comparison of 68Ga-Labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography/Magnetic Resonance Imaging and Positron Emission Tomography/Computed Tomography for Primary Staging of Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol Open Sci, 33: 61–71. [29] Skawran SM, Sanchez V, Ghafoor S, et al., 2022, Primary Staging in Patients with Intermediate- and High-Risk Prostate Cancer: Multiparametric MRI and 68Ga-PSMA-PET/MRI - What Is the Value of Quantitative Data from Multiparametric MRI Alone or in Conjunction with Clinical Information? Eur J Radiol, 146: 110044. [30] Privé BM, Israël B, Schilham MGM, et al., 2021, Evaluating F-18-PSMA-1007-PET in Primary Prostate Cancer and Comparing it to Multi-Parametric MRI and Histopathology. Prostate Cancer Prostatic Dis, 24(2): 423–430.